News
PYXS
1.580
0.00%
0.000
Pyxis Oncology Stockholders Approve Authorized Share Increase
TipRanks · 10h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CervoMed (CRVO), Pyxis Oncology (PYXS) and Moderna (MRNA)
TipRanks · 4d ago
Weekly Report: what happened at PYXS last week (1102-1106)?
Weekly Report · 4d ago
Pyxis Oncology Is Maintained at Outperform by RBC Capital
Dow Jones · 11/06 18:59
Pyxis Oncology Price Target Raised to $7.00/Share From $6.00 by RBC Capital
Dow Jones · 11/06 18:59
RBC Capital Maintains Outperform on Pyxis Oncology, Raises Price Target to $7
Benzinga · 11/06 18:49
Pyxis Oncology Is Maintained at Outperform by Wedbush
Dow Jones · 11/06 17:07
Pyxis Oncology Price Target Cut to $7.00/Share From $8.00 by Wedbush
Dow Jones · 11/06 17:07
Wedbush Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7
Benzinga · 11/06 16:57
Guggenheim Keeps Their Buy Rating on Pyxis Oncology (PYXS)
TipRanks · 11/06 14:22
Pyxis Oncology price target lowered to $7 from $8 at Wedbush
TipRanks · 11/06 13:40
Pyxis Oncology price target lowered to $5 from $7 at Stifel
TipRanks · 11/06 12:20
Pyxis Oncology, Inc. Reports Third Quarter 2026 Financial Results
NASDAQ · 11/06 00:01
Pyxis Oncology GAAP EPS of -$0.24 beats by $0.04
Seeking Alpha · 11/05 12:58
Pyxis Oncology Q3 EPS $(0.24) Beats $(0.29) Estimate
Benzinga · 11/05 12:37
*Pyxis Oncology 3Q Loss/Shr 24c >PYXS
Dow Jones · 11/05 12:05
Press Release: Pyxis Oncology Reports Third -2-
Dow Jones · 11/05 12:00
Press Release: Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)
Dow Jones · 11/05 12:00
Weekly Report: what happened at PYXS last week (1026-1030)?
Weekly Report · 11/02 09:21
Russell 2000 estimated to add 107 stocks in December rebalance - Stephens
Seeking Alpha · 10/29 19:12
More
Webull provides a variety of real-time PYXS stock news. You can receive the latest news about Pyxis Oncology, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PYXS
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.